Disomotide is an oligopeptide in phase III clinical development for the treatment of melanoma. Vaccination with the disomotide peptide has resulted in very high levels of circulating T cells that were capable of recognizing and killing melanoma cancer cells in vitro. In a single-group, phase 2 study, patients with metastatic melanoma were immunized with the disomotide peptide vaccine in Montanide ISA-51 (incomplete Freund’s adjuvant), followed by high-dose interleukin-2, leading to objective clinical responses in 13 of 31 patients. Randomized study showed the clinical benefit of a vaccine in the treatment of patients with measurable metastatic melanoma. Patients receiving the disomotide with interleukin-2 were more than twice as likely to have a clinical response as those receiving interleukin-2 alone.
Approval Year
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C1752
Created by
admin on Sat Dec 16 00:43:22 GMT 2023 , Edited by admin on Sat Dec 16 00:43:22 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
CHEMBL263429
Created by
admin on Sat Dec 16 00:43:22 GMT 2023 , Edited by admin on Sat Dec 16 00:43:22 GMT 2023
|
PRIMARY | |||
|
657090
Created by
admin on Sat Dec 16 00:43:22 GMT 2023 , Edited by admin on Sat Dec 16 00:43:22 GMT 2023
|
PRIMARY | |||
|
RR-78
Created by
admin on Sat Dec 16 00:43:22 GMT 2023 , Edited by admin on Sat Dec 16 00:43:22 GMT 2023
|
PRIMARY | |||
|
C76227
Created by
admin on Sat Dec 16 00:43:22 GMT 2023 , Edited by admin on Sat Dec 16 00:43:22 GMT 2023
|
PRIMARY | |||
|
DTXSID50171158
Created by
admin on Sat Dec 16 00:43:22 GMT 2023 , Edited by admin on Sat Dec 16 00:43:22 GMT 2023
|
PRIMARY | |||
|
8028PPX4PM
Created by
admin on Sat Dec 16 00:43:22 GMT 2023 , Edited by admin on Sat Dec 16 00:43:22 GMT 2023
|
PRIMARY | |||
|
8694
Created by
admin on Sat Dec 16 00:43:22 GMT 2023 , Edited by admin on Sat Dec 16 00:43:22 GMT 2023
|
PRIMARY | |||
|
181477-43-0
Created by
admin on Sat Dec 16 00:43:22 GMT 2023 , Edited by admin on Sat Dec 16 00:43:22 GMT 2023
|
PRIMARY |
ACTIVE MOIETY